Funxional Therapeutics Co

News

26 May 2010

Funxional Therapeutics raises 10 million Euros in a private Series B financing round to fund the initial Phase II clinical studies of FX125L in inflammation.

FXT Series B Financing Press Release PDF

 

8 January 2010

Funxional Therapeutics Announces successful completion of the Phase I Programme of its Novel Anti-inflammatory Small Molecule, FX125L

FXT03 Press Release PDF

9 November 2009

The presentation of the first clinical results of FX125L made at the American College of Allergy, Asthma & Immunology (ACAAI) 2009 Annual Scientific Meeting on November 8th 2009, captured the interests of medical journalists and articles about it have appeared in specialised internet sites.

News about the study results and FX125L featured in various sections of Medscape, Reuter Health Stories for decision makers in Respiratory care and Medpage today.

14 September 2009

The abstract with the results from the first clinical trial with FX125L has been accepted for an oral presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2009 Annual Meeting, November 5-10, Miami Beach (FL), USA.

3 August 2009

FX125L and BSCIs were the subject of the Product Development Report section in this week’s BioCentury. The article highlighted key features of FX125L and of BSCIs and provided some elements of the development strategy of the product.

Go to article

8 July 2009

Funxional successfully completes initial clinical trial of FX125L, an anti-inflammatory drug with a novel mechanism of action.

FXT 02 Press Release PDF

10 June 2009

Dr David Grainger,  FXT’s co-Founder and CSO, presented today in the Late Breaking session of the EAACI 2009 results from studies in an animal model of allergic asthma, which showed that FX125L attenuates neutrophil accumulation and exhibits a superior efficacy profile to dexamethasone or montelucast.

23 January 2009

The US FDA approved the IND application of FX125L for the treatment of asthma.

 

Events

Please check again for future events that Funxional Therapeutics will be attending.